Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) insider Jason Patrick Meyenburg purchased 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were purchased at an average cost of $12.13 per share, with a total value of $48,520.00. Following the completion of the acquisition, the insider now directly owns 30,228 shares in the company, valued at $366,665.64. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Sucampo Pharmaceuticals, Inc. (SCMP) traded up 0.41% during trading on Friday, hitting $12.35. 366,567 shares of the company’s stock were exchanged. The stock’s market cap is $572.11 million. Sucampo Pharmaceuticals, Inc. has a 1-year low of $9.30 and a 1-year high of $17.55. The stock’s 50-day moving average price is $10.97 and its 200-day moving average price is $10.66.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. The firm had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.24 earnings per share. On average, equities analysts expect that Sucampo Pharmaceuticals, Inc. will post $1.02 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Sucampo Pharmaceuticals, Inc. (SCMP) Insider Jason Patrick Meyenburg Buys 4,000 Shares” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/08/sucampo-pharmaceuticals-inc-scmp-insider-jason-patrick-meyenburg-buys-4000-shares.html.

Several equities analysts recently issued reports on the stock. Leerink Swann assumed coverage on shares of Sucampo Pharmaceuticals in a report on Monday, August 21st. They set an “outperform” rating and a $15.00 price target for the company. Maxim Group reissued a “buy” rating and set a $23.00 price target (up from $21.00) on shares of Sucampo Pharmaceuticals in a report on Tuesday, August 8th. BidaskClub downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 5th. Roth Capital set a $30.00 price target on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 3rd. Finally, TheStreet downgraded shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $17.63.

Several hedge funds have recently bought and sold shares of SCMP. NEA Management Company LLC bought a new position in shares of Sucampo Pharmaceuticals in the second quarter worth about $13,214,000. Rubric Capital Management LP bought a new position in Sucampo Pharmaceuticals in the 2nd quarter valued at approximately $6,068,000. Vanguard Group Inc. raised its holdings in Sucampo Pharmaceuticals by 48.9% in the 1st quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock valued at $16,024,000 after buying an additional 478,226 shares during the last quarter. Royce & Associates LP raised its holdings in Sucampo Pharmaceuticals by 24.6% in the 1st quarter. Royce & Associates LP now owns 974,023 shares of the biopharmaceutical company’s stock valued at $10,714,000 after buying an additional 192,000 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Sucampo Pharmaceuticals by 107.3% in the 1st quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock valued at $4,044,000 after buying an additional 190,292 shares during the last quarter. 55.44% of the stock is owned by hedge funds and other institutional investors.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.